文献速递脑血管病

连续添加生物标志物对房颤卒中与出血风险预测的优化

Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores.
PubMed 文献 · Stroke · 2019-05-14

本研究纳入940例稳定使用维生素K拮抗剂的房颤患者,评估在CHA2DS2-VASc和HAS-BLED评分中连续添加不同生物标志物能否提升风险预测。随访6.5年,缺血性卒中与大出血年发生率均为1.60%;添加生物标志物未显著提高CHA2DS2-VASc对卒中的预测,仅轻微增强HAS-BLED对大出血的预测,临床净获益有限。

要点

  • 连续添加生物标志物未显著提升CHA2DS2-VASc对缺血性卒中的预测性能。
  • 添加3种生物标志物(VWF+NT-proBNP+hsIL-6)仅轻微增强HAS-BLED对大出血的预测。
  • 基于生物标志物的模型相比原临床评分净获益和临床实用性有限。

核心结论

  • 连续添加生物标志物未提高CHA2DS2-VASc对缺血性卒中的预测能力,仅轻微增强HAS-BLED对大出血的预测,净获益有限。

研究设计与样本

  • 纳入940例稳定使用维生素K拮抗剂(INR 2.0-3.0)至少6个月的房颤患者,量化6种生物标志物并随访记录不良事件。

主要发现

  • 随访6.5(4.3-7.9)年,发生98例缺血性卒中(1.60%/年)和172例大出血(1.60%/年)。
  • 添加3种生物标志物(NT-proBNP+BTP+VWF)后CHA2DS2-VASc模型敏感性轻度提升(IDI 2.70%;P<0.001)。
  • HAS-BLED在所有生物标志物模型中预测性能增强,最佳模型(VWF+NT-proBNP+hsIL-6)C指数0.600(95%CI 0.561-0.625) vs 0.639(95%CI 0.607-0.669);P=0.025。
  • 该模型IDI 5.20%(P<0.001),NRI 19.20%(P=0.020)。

关键数值与推荐

  • CHA2DS2-VASc添加3种生物标志物后IDI 2.70%(P<0.001),但整体预测性能未显著增加。
  • HAS-BLED最佳模型C指数0.600(95%CI 0.561-0.625) vs 0.639(95%CI 0.607-0.669);P=0.025。
  • 最佳模型IDI 5.20%(P<0.001),NRI 19.20%(P=0.020)。

临床怎么用

  • 在房颤抗凝患者中,常规添加多种生物标志物对卒中风险预测的增量价值有限,不应替代临床评分。
  • 对出血风险预测,可考虑VWF+NT-proBNP+hsIL-6组合轻微改善HAS-BLED,但净获益有限,需结合临床判断。

局限性

  • 研究人群为稳定使用维生素K拮抗剂者,结果可能不适用于直接口服抗凝药患者。
  • 生物标志物模型的净获益和临床实用性相比原评分仅为边际改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Current European guidelines for the management of atrial fibrillation suggest using biomarkers to refine the risk stratification process. However, it is unclear whether ≥2 biomarkers incrementally improve risk prediction beyond 1 biomarker alone. We investigated whether the predictive performance of CHA2DS2-VASc and HAS-BLED scores could be enhanced by incrementally adding consecutive different biomarkers in real-world atrial fibrillation patients taking vitamin K antagonists therapy. Methods- We included 940 atrial fibrillation patients stable on vitamin K antagonists (international normalized ratio, 2.0-3.0) for at least the previous 6 months. At inclusion, VWF (von Willebrand factor), high-sensitivity troponin T, NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity IL (interleukin)-6, fibrin monomers, and BTP (β-trace protein) concentrations were quantified. During follow-up, all adverse events were recorded, and biomarkers were added to CHA2DS2-VASc and HAS-BLED scores depending on the C index. Results- During 6.5 (4.3-7.9) years, there were 98 ischemic strokes (1.60% per year) and 172 major bleeds (1.60% per year). After the addition of biomarkers, the predictive performance of CHA2DS2-VASc was not significantly increased, although the model with 3 biomarkers (ie, NT-proBNP+BTP+VWF) showed a low gain in sensitivity (integrated discrimination improvement, 2.70%; P<0.001). The predictive performance of HAS-BLED was enhanced in all biomarker-based models, with the best prediction shown by the model with 3 biomarkers (ie, VWF+NT-proBNP+high-sensitivity IL-6; C index, 0.600 [95% CI, 0.561-0.625] versus 0.639 [95% CI, 0.607-0.669]; P=0.025). This model also confirmed an increased sensitivity (integrated discrimination improvement, 5.20%; P<0.001) and positive reclassification (net reclassification improvement, 19.20%; P=0.020). Conclusions- By adding consecutive biomarkers, the predictive ability of CHA2DS2-VASc for ischemic stroke was not increased, whereas the predictive ability of HAS-BLED for major bleeding was only slightly enhanced. The net benefit and clinical usefulness of the biomarker-based models were marginal in comparison to the original scores based on clinical factors.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Rivera-Caravaca JM, Marín F, Vilchez JA, et al. Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke. 2019. PMID: 31084333. doi:10.1161/STROKEAHA.118.024305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。